299. Cystic fibrosis Clinical trials / Disease details

Clinical trials : 1,696 / Drugs : 1,644 - (DrugBank : 272) / Drug target genes : 96 - Drug target pathways : 170

3 trials found

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT02323100 (ClinicalTrials.gov)	December 2, 2018	18/12/2014	Glycerol Phenylbutyrate Corrector Therapy For CF (Cystic Fibrosis)	A Double Blind, Placebo Controlled, Dose Escalation Trial of Glycerol Phenylbutyrate Corrector Therapy for Cystic Fibrosis	Cystic Fibrosis	Drug: Ravicti low dose;Drug: Ravicti high dose;Drug: Placebo	National Jewish Health	University of Alabama at Birmingham;Children's Hospital of Philadelphia;Johns Hopkins University;Horizon Pharma Ireland, Ltd., Dublin Ireland	Recruiting	18 Years	N/A	All	36	Phase 1/Phase 2	United States
2	NCT00590538 (ClinicalTrials.gov)	February 2003	27/12/2007	Phenylbutyrate/Genistein Duotherapy in Delta F508-Heterozygotes (for Cystic Fibrosis)	A Pilot Trial of Phenylbutyrate/Genistein Duotherapy in Delta F508-Heterozygous Cystic Fibrosis Patients	Cystic Fibrosis	Drug: Sodium 4-Phenylbutyrate;Drug: Genistein (Unconjugated Isoflavones 100);Drug: Placebo	Children's Hospital of Philadelphia	Cystic Fibrosis Foundation Therapeutics	Terminated	18 Years	N/A	All	9	Phase 1/Phase 2	United States
3	NCT00016744 (ClinicalTrials.gov)	September 2001	31/5/2001	Phenylbutyrate/Genistein Duotherapy in Delta F508-Homozygous(for Cystic Fibrosis)	A Pilot Trial of Phenylbutyrate/Genistein Duotherapy in Delta F508-Homozygous Cystic Fibrosis Patients	Cystic Fibrosis	Drug: Sodium 4-Phenylbutyrate (4PBA);Drug: Unconjugated Isoflavones 100 (PTI G-4660, 87% Genistein);Drug: Placebo	Children's Hospital of Philadelphia	Cystic Fibrosis Foundation Therapeutics;National Center for Research Resources (NCRR)	Completed	18 Years	N/A	Both	12	Phase 1/Phase 2	United States